Two-weekly dose-adjusted (DA)-EPOCH-like chemotherapy with high-dose dexamethasone plus rituximab (DA-EDOCH14-R) in poor-prognostic untreated diffuse large B-cell lymphoma

British Journal of Haematology

Volumn 160, Issue 4, 2013, Pages 510-514

  García Suárez, Julio ^a   Flores, Elena ^a   Callejas, Marta ^a   Arribas, Ignacio ^a   Gil Fernández, Juan José ^a   Olmedilla, Gabriel ^a   Curto, Natalia ^a   Guillén, Helga ^a   Casco, Celia Rosalva ^a   Martín, Yolanda ^a   Burgaleta, Carmen ^a  

^a HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

Author keywords

CNS events; DA EDOCH14 R; High dose dexamethasone; Poor risk diffuse large B cell lymphoma; Rituximab

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ANEMIA; ARTICLE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGESTIVE SYSTEM DISEASE; DIGESTIVE TRACT MUCOSITIS; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; INFECTION; LARGE CELL LYMPHOMA; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PREDNISONE; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINCRISTINE; YOUNG ADULT;

EID: 84873093053     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12144     Document Type: Article

References (15)

1. Boehme, V., Zeynalova, S., Kloess, M., Loeffler, M., Kaiser, U., Pfreundschuh, M. & Schmitz, N. (2007) Incidence and risk factors of central nervous system recurrence in aggressive lymphoma-a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Annals of Oncology, 18, 149-157.
2. Brusamolino, E., Rusconi, C., Montalbetti, L., Gargantini, L., Uziel, L., Pinotti, G., Fava, S., Rigacci, L., Pagnucco, G., Pascutto, C., Morra, E. & Lazzarino, M. (2006) Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity. Haematologica, 91, 496-502.
3. Cheson, B.D., Pfistner, B., Juweid, M.E., Gascoyne, R.D., Specht, L., Horning, S.J., Coiffier, B., Fisher, R.I., Hagenbeek, A., Zucca, E., Rosen, S.T., Stroobants, S., Lister, T.A., Hoppe, R.T., Dreyling, M., Tobinai, K., Vose, J.M., Connors, J.M., Federico, M. & Diehl, V. (2007) Revised response criteria for malignant lymphoma. Journal of Clinical Oncology, 25, 579-586.
4. Cunningham, D., Smith, P., Mouncey, P., Qian, W., Jack, A.S., Pocock, C., Ardeshna, K., Radford, J.A., Davies, A.J., McMillan, A. & Linch, M.D. (2011) R-CHOP14 versus R-CHOP21: Result of a randomized phase III trial for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma. Journal of Clinical Oncology, 29(Suppl; abstract 8000).
5. Dunleavy, K., Little, R.F., Pittaluga, S., Grant, N., Wayne, A.S., Carrasquillo, J.A., Steinberg, S.M., Yarchoan, R., Jaffe, E.S. & Wilson, W.H. (2010) The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. Blood, 115, 3017-3024.
6. García-Suárez, J., Bañas, H., Arribas, I., De Miguel, D., Pascual, T. & Burgaleta, C. (2007) Dose-adjusted EPOCH plus rituximab is an effective regimen in patients with poor-prognostic untreated diffuse large B-cell lymphoma: results from a prospective observational study. British Journal of Haematology, 136, 276-285.
7. Greb, A., Bohlius, J., Trelle, S., Schiefer, D., De Souza, C.A., Gisselbrecht, C., Intragumtornchai, T., Kaiser, U., Kluin-Nelemans, H.C., Martelli, M., Milpied, N.J., Santini, G., Verdonck, L.F., Vitolo, U., Schwarzer, G. & Engert, A. (2007) High-dose chemotherapy with autologous stem cell support in first line treatment of aggressive non-Hodgkin lymphoma- results of a comprehensive meta-analysis. Cancer Treatment Reviews, 33, 338-346.
8. Hans, C.P., Weisenburger, D.D., Greiner, T.C., Gascoyne, R.D., Delabie, J., Ott, G., Muller-Hermelink, H.K., Campo, E., Braziel, R.M., Jaffe, E.S., Pan, Z., Farinha, P., Smith, L.M., Falini, B., Banham, A.H., Rosenwald, A., Staudt, L.M., Connors, J.M., Armitage, J.O. & Chan, W.C. (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood, 103, 275-282.
9. Niitsu, N., Kohri, M., Hagiwara, Y., Tanae, K., Takahashi, N., Bessho, M. & Okamoto, M. (2010) Multicentre phase II study of CyclOBEAP plus rituximab in patients with diffuse large B-cell lymphoma. Hematological Oncology, 28, 68-74.
10. Pfreundschuh, M., Trumper, L., Kloess, M., Schmits, R., Feller, A.C., Rube, C., Rudolph, C., Reiser, M., Hossfeld, D.K., Eimermacher, H., Hasenclever, D., Schmitz, N. & Loeffler, M. (2004) Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood, 104, 634-641.
11. Rose, A.L., Smith, B.E. & Maloney, D.G. (2002) Glucocorticoids and rituximab in vitro: synergistic direct antiproliferative and apoptotic effects. Blood, 100, 1765-1773.
12. Schmitz, N., Nickelsen, M., Ziepert, M., Haenel, M., Borchmann, P., Viardot, A., Nickenig, C., Bentz, M., Peschel, C., Trümper, L., Loeffler, M., Pfreundschuh, M. & Glass, B. (2009) Aggressive chemotherapy (CHOEP-14) and rituximab or high-dose therapy (MegaCHOEP) and rituximab for young high-risk patients with aggressive B-cell lymphoma: results of the MegaCHOEP trial of the German High-Grade Non-Hodgkin Lymphoma study group (DSHNHL). Blood (ASH Annual Meeting Abstracts), 114(Abstract 404).
13. Schmitz, N., Zeynalova, S., Glass, B., Kaiser, U., Cavallin-Stahl, E., Wolf, M., Haenel, M., Loeffler, M., Truemper, L. & Pfreundschuh, M. (2012) CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group. Annals of Oncology, 23, 1267-1273.
14. Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., Thiele, J. & Vardiman, J.W. (eds) (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue. IARC Press, Lyon.
15. Wilson, W.H., Dunleavy, K., Pittaluga, S., Hegde, U., Grant, N., Steinberg, S.M., Raffeld, M., Gutierrez, M., Chabner, B.A., Staudt, L., Jaffe, E.S. & Janik, J.E. (2008) Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. Journal of Clinical Oncology, 26, 2717-2724.